Cloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients
NCT ID: NCT00885300
Last Updated: 2009-04-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2008-01-31
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid in Colistin-Induced Nephrotoxicity
NCT06650384
A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia
NCT00614679
Study of CXA-10 in Healthy Volunteers
NCT02127190
Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients
NCT02159859
Optimalization of Nephroprotection Using N-Acetylcysteine
NCT00572663
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
cloxacillin 100 mg/ml + heparin 1000iu/ml as catheter lock at the end of hemodialysis
cloxacillin
cloxacillin 100mg/ml as catheter lock at the end of hemodialysis
heparin
heparin 1000iu/ml as catheter lock at the end of hemodialysis
2
heparin 1000iu/ml as catheter lock at the end of hemodialysis
heparin
heparin 1000iu/ml as catheter lock at the end of hemodialysis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cloxacillin
cloxacillin 100mg/ml as catheter lock at the end of hemodialysis
heparin
heparin 1000iu/ml as catheter lock at the end of hemodialysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* at least 2 time dialysis/week
Exclusion Criteria
* acute renal failure
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shiraz University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shiraz University of Medical Science
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
maryam pakfetart, assistant professor
Role: STUDY_CHAIR
Shiraz nephro-urology research center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shiraz University Hemodialysis Center
Shiraz, Fars, Iran
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Unver S, Atasoyu EM, Evrenkaya TR, Ardic N, Ozyurt M. Risk factors for the infections caused by temporary double-lumen hemodialysis catheters. Arch Med Res. 2006 Apr;37(3):348-52. doi: 10.1016/j.arcmed.2005.07.010.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3705
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.